Free Newsletter Sign-up!
Submit
#1 Source  for Gaining Ideas!
Get Quote: Go Find Symbol

Dendreon Corporation / Nasdaq: DNDN

View 1 year chart below to see when DNDN went from $5 to $25 per share.

INVESTORS MAY HAVE CHANCE FOR 500% GAIN AGAIN

Research corporate news archives to discover why DNDN exploded in the first place.

  • March 29, 2007: Dendreon Corp. Receives Recommendation from FDA Advisory Board Committee for their Prostate Cancer immunotherapy Provenge®
  • May 9, 2007: Dendreon Corp. Receives Response Letter from FDA Requesting Additional Clinical Data

FULL DNDN QUOTE NOW

JANUARY 15, 2008: Dendreon Receives European Patent Covering PROVENGE® and Company's ACI Platform Technology

We believe that Dendreon Corporation (NASDAQ: DNDN) will utimately receive FDA approval for Provenge® within the next 12 to 18 months.

Aggressive investors may want to consider 2009 and 2010 Call Options.

the OTC Money Group